Last Update 15 Jun 26
Fair value Increased 3.83%EKTA B: Future Returns Will Rely On Margin Delivery Versus Cautious Ratings
The updated analyst price target for Elekta moves to SEK 60.50 from SEK 58.27, with analysts pointing to slightly higher assumed profit margins, a modestly lower discount rate and a stable forward P/E outlook, even as some recent research has turned more cautious on the stock.
Analyst Commentary
Recent Street research around Elekta points to a mixed setup, with some analysts turning more cautious even as valuation remains anchored by the updated SEK 60.50 price target and a stable forward P/E framework.
Bullish Takeaways
- Bullish analysts see the current SEK 60.50 target as supported by slightly higher assumed profit margins, which they view as constructive for earnings quality over time.
- The modestly lower discount rate used in revised models suggests a bit more confidence in Elekta's risk profile and cash flow visibility, which can support the updated target level.
- Stable forward P/E assumptions indicate that, at current valuation, analysts still see room for Elekta to justify its pricing through consistent execution rather than relying on aggressive multiple expansion.
Bearish Takeaways
- Bearish analysts have shifted to more neutral ratings, such as Hold. At around the SEK 58 to SEK 60.50 reference range, they see a more balanced risk and reward profile.
- Some research has turned more cautious on the stock, suggesting concern that execution or margin delivery may need to improve further to support upside beyond the current valuation assumptions.
- The SEK 58 price target cited in recent research sits below the updated SEK 60.50 level, which signals that not all analysts are aligned on the upside case around profit margins and discount rate assumptions.
- Overall, the tilt toward Hold ratings highlights that, while the investment case is not seen as broken, expectations for near term outperformance are more restrained and closely tied to delivery against margin and P/E assumptions.
What's in the News
- Elekta issued earnings guidance for fiscal year 2026/2027, indicating that it expects net sales in constant currency to be higher year over year, with an improvement in the EBIT margin. (Source: Company guidance)
- The company initiated a voluntary Class II recall of its Leksell Vantage Arc System after identifying that locking mechanisms may not properly secure, which can affect coordinate stability during neurosurgical or stereotactic procedures. (Source: FDA Enforcement Report, 09 May 2026)
- The recall covers about 768 units across multiple U.S. states and international markets, with the FDA classifying the issue as having a low probability of serious harm and potential for temporary or medically reversible adverse health consequences. (Source: FDA Enforcement Report, Recall Number Z-2006-2026)
Valuation Changes
- Fair Value: SEK 60.50, up slightly from SEK 58.27, reflecting a modest increase in the central valuation anchor used by analysts.
- Discount Rate: 6.33%, down slightly from 6.59%, implying a small adjustment to Elekta's assessed risk profile in updated models.
- Revenue Growth: 4.29%, down from 4.81%, indicating a more cautious assumption for future SEK revenue expansion.
- Net Profit Margin: 9.45%, up from 8.94%, signaling slightly higher expected earnings efficiency on future SEK sales.
- Future P/E: 15.51x, up marginally from 15.29x, pointing to a small change in how much investors are assumed to be willing to pay for Elekta's expected earnings.
4 viewsusers have viewed this narrative update
Key Takeaways
- Successful software launches and service expansion are boosting sales growth, margins, and predictable cash flow, especially as global adoption of precision radiotherapy accelerates.
- Market recovery in China and emerging regions, supported by cost control and strong cancer treatment demand, positions Elekta for sustained earnings and multi-year revenue growth.
- Margin and earnings outlook is pressured by tariff and FX headwinds, weak order trends, regional uncertainty, rising costs, and intensifying competitive and regulatory challenges.
Catalysts
About Elekta- A medical technology company, provides clinical solutions for treating cancer and brain disorders in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
- Continued strong momentum and successful launches of Elekta Evo and Elekta ONE software in Europe are driving double-digit sales growth and gross margin improvement in the region; this suggests that further global rollouts of these advanced solutions, aligned with increasing demand for precision radiotherapy, may accelerate overall revenue and margin expansion as adoption broadens.
- Rebuilding of the order backlog and anticipated return to growth in China in the second half of the fiscal year, underpinned by Elekta's leading market position and government-supported cancer programs, points to renewed access to a large addressable market and significant top-line growth potential.
- Expansion of high-margin service and software recurring revenue, evidenced by consistent 4% service growth and increasing software traction, adds predictable cash flow and supports higher net margins as more customers attach ongoing digital and planning solutions to hardware sales.
- Cost rationalization measures-including SG&A reductions and supply chain productivity enhancements-are actively offsetting headwinds from tariffs and FX, putting Elekta on a path to regain pre-pandemic gross margin and EBIT margin levels, thereby supporting medium-term earnings recovery.
- A rising global cancer burden from aging populations, combined with infrastructure growth in emerging markets like India and China, ensures a sustained, long-term demand backdrop for advanced radiotherapy solutions-underpinning a multi-year revenue growth profile for Elekta if current valuation discounts this opportunity.
Elekta Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming Elekta's revenue will grow by 4.3% annually over the next 3 years.
- Analysts assume that profit margins will increase from -3.1% today to 9.4% in 3 years time.
- Analysts expect earnings to reach SEK 1.8 billion (and earnings per share of SEK 4.68) by about June 2029, up from -SEK 519.0 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting SEK2.1 billion in earnings, and the most bearish expecting SEK1.1 billion.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 15.5x on those 2029 earnings, up from -38.6x today. This future PE is lower than the current PE for the GB Medical Equipment industry at 32.0x.
- Analysts expect the number of shares outstanding to remain consistent over the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 6.33%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- Ongoing and increasing tariff and FX headwinds are putting significant pressure on Elekta's gross margin and EBIT margin, and while management is taking action through pricing and cost optimization, there is limited ability to pass on price increases to existing backlog orders, directly impacting net margins and earnings.
- Order softness and delayed revenue recognition in two historically high-margin regions (the U.S. and China) due to FDA approval delays for new products and a thin order backlog in China could result in weaker top-line growth and sustained regional revenue/margin volatility.
- Elekta's guidance and growth outlook rely heavily on an eventual recovery in China and strong momentum in Europe, but both regions face risks: China's recovery is based on a still-rebuilding order book and unpredictable macro/policy factors, and European growth may not be sustainable at current high levels, leading to risk for both revenue stability and forward-looking cash generation.
- Increasing net R&D costs, coupled with a declining trend in R&D capitalization rates, may limit margin improvement in the medium term, particularly if gross margin pressure from FX and tariffs persists and if innovation spending does not translate quickly enough into profitable new products.
- Market dynamics such as greater buyer consolidation, continued regulatory/regional uncertainty (notably around U.S. approvals), and heightened global pricing competition (including from Asian entrants) may compress Elekta's future net margins and challenge currently anticipated earnings expansion.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of SEK60.5 for Elekta based on their expectations of its future earnings growth, profit margins and other risk factors.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of SEK100.0, and the most bearish reporting a price target of just SEK41.0.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be SEK19.0 billion, earnings will come to SEK1.8 billion, and it would be trading on a PE ratio of 15.5x, assuming you use a discount rate of 6.3%.
- Given the current share price of SEK52.4, the analyst price target of SEK60.5 is 13.4% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Elekta?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Read more narratives
SEK 92.79
FV
49.4% undervalued intrinsic discount16
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
SEK 39
FV
20.5% overvalued intrinsic discount19
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative